The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry. Objectives: The aim of this paper is to provide a European overview of (lis...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Pharmacol
Main Authors: Moorkens, Evelien, Godman, Brian, Huys, Isabelle, Hoxha, Iris, Malaj, Admir, Keuerleber, Simon, Stockinger, Silvia, Mörtenhuber, Sarah, Dimitrova, Maria, Tachkov, Konstantin, Vončina, Luka, Palčevski, Vera Vlahović, Achniotou, Gnosia, Slabý, Juraj, Popelková, Leona, Kohoutová, Kateřina, Bartels, Dorthe, Laius, Ott, Martikainen, Jaana E., Selke, Gisbert W., Kourafalos, Vasileios, Magnússon, Einar, Einarsdóttir, Rannveig, Adams, Roisín, Joppi, Roberta, Allocati, Eleonora, Jakupi, Arianit, Viksna, Anita, Greičiūtė-Kuprijanov, Ieva, Vella Bonanno, Patricia, Suttorp, Vincent, Melien, Øyvind, Plisko, Robert, Mardare, Ileana, Meshkov, Dmitry, Novakovic, Tanja, Fürst, Jurij, Zara, Corinne, Marković-Peković, Vanda, Grubiša, Nataša, Befrits, Gustaf, Puckett, Robert, Vulto, Arnold G.
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2021
Teme:
Pharmacology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839249/
https://ncbi.nlm.nih.gov/pubmed/33519450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.591134
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki